Diabesity Rounds

Retatrutide vs tirzepatide

Retatrutide acts on GIP, GLP-1 and glucagon receptors and is still in trials. Tirzepatide acts on GIP and GLP-1 receptors and is already in use. This page brings together our reports on each, and on studies that looked at both.

What our reports show

No report on this page compared retatrutide with tirzepatide directly, so our reports cannot show which performs better. Each drug was studied in different patients, against different comparators.

For retatrutide, both reports are phase 3 placebo-controlled trials in adults with a BMI of at least 27. In the knee osteoarthritis trials, in people without diabetes, WOMAC pain fell more than with placebo at 68 and 80 weeks. In TRIUMPH-4, body weight changed by -20.0% (9 mg) and -23.7% (12 mg), versus -4.6% with placebo. Serious adverse events were more common with retatrutide. In the sleep apnoea trials, the apnoea-hypopnoea index fell more than with placebo at 80 weeks, with or without type 2 diabetes. The authors call retatrutide investigational.

For tirzepatide, the evidence is of a different kind. An open-label registry record in 794 adults with early type 2 diabetes reported HbA1c change at week 104 of -2.24 percentage points with tirzepatide and -1.45 with intensified conventional care. A 40-week trial of 120 adults on tirzepatide found that adding resistance exercise reduced lean soft tissue loss (-3.57 kg versus -4.67 kg). A meta-analysis that pooled five randomised trials with two observational studies found hsCRP lower by 34.3% and NT-proBNP lower by 17.6%.

These results cannot be set side by side. The comparators were placebo, intensified conventional care, placebo or standard of care (meta-analysis), and usual activities in a trial where all participants took tirzepatide and the exercise add-on was what was tested. The endpoints were pain, apnoea index, HbA1c, lean mass and biomarkers. Trial durations ranged from 40 to 104 weeks; the meta-analysis did not report follow-up length, and the populations differed. Most endpoints are surrogate measures. Only a head-to-head trial could answer the comparison.

Written only from the reports below and checked against them. Updated 13 November 2026.

Studies that looked at both

None of our reports so far has covered a study of both. This list updates itself when one is published.

Retatrutide

Tirzepatide

For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 14 November 2026.